Pneumonia in the ImmunoCompromised: Use of the Karius Test® for the Detection of Undiagnosed Pathogens
The Karius Test® is a liquid biopsy for infection diseases that utilizes microbial cell-free DNA in plasma to detect over 1000 pathogens causing deep-seated and bloodstream infections. During his presentation Dr. Bergin will provide an overview of the Karius multi-center, prospective study comparing the Karius Test to Standard of Care in immunocompromised (IC) patients being evaluated for pneumonia. The population for this study are IC adults with hematological malignancies and/or hematocrit (HCT) with suspicion of pneumonia. Results are expected later in 2022.
*This program is sponsored by Karius and CME credit is not available for this event.
Assistant Professor of Medicine
Director, Fellowship Training Programs
Pulmonary and Critical Care Medicine
Duke University Health System
Abstracts & Posters
ATS Quiz 2022
About the Karius Test
The Karius Test is a liquid biopsy needing only a single blood sample to rapidly and non-invasively detect over 1,000 pathogens causing deep-seated and bloodstream infections.
Stay up-to-date with Karius
Sign up today to receive notifications of upcoming events and presentations by physicians using the Karius Test in clinical practice.